Joinn Biologics, a CDMO based in the USA, has completed the acquisition of Lonza’s 183,000 sq. ft (17,000 m2) manufacturing plant in Guangzhou, as part of the company’s strategy to increase its presence in China’s Greater Bay Area and enhance its service offerings across the Asia-Pacific region.

The facility is equipped with advanced modular and digital production workshops, enabling both small-batch and large-scale biologics manufacturing, which the company plans to utilise to provide comprehensive services – including cell line production, process development, and formulation production.